| Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC | 09/20 08:30 | globenewswire.com |
| Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference | 08/22 08:30 | globenewswire.com |
| Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update | 08/14 16:02 | globenewswire.com |
| Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers | 06/25 08:30 | globenewswire.com |
| Alpha Tau to Present at the Jefferies Global Healthcare Conference | 05/21 08:45 | globenewswire.com |
| Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update | 05/20 16:01 | globenewswire.com |
| Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer | 05/13 08:30 | globenewswire.com |
| Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow | 05/06 08:30 | globenewswire.com |
| Alpha Tau to Participate in May Investor Conferences | 05/01 08:30 | globenewswire.com |
| Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit | 03/25 08:50 | globenewswire.com |